STOCK TITAN

Broadwood and Neal Bradsher hold 39.7% of Insight Molecular (IMDX) shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Broadwood Partners, Broadwood Capital and Neal C. Bradsher report beneficial ownership of 12,835,134 Insight Molecular Diagnostics shares, representing 39.7% of the common stock. The amendment reflects an updated ownership percentage based on 32,318,071 shares outstanding, adjusted to include warrants they beneficially own.

Broadwood Partners and Broadwood Capital each report shared voting and dispositive power over 12,834,977 shares, while Mr. Bradsher also holds 157 shares with sole voting and dispositive power. The group funded its investment from working capital and personal funds, without dedicated borrowing beyond ordinary-course working capital.

The reporting persons state they will continue to review their investment and may discuss strategic alternatives with management, the board and other shareholders, and reserve the right to pursue various transactions or actions in compliance with securities laws.

Positive

  • None.

Negative

  • None.

Insights

Broadwood and Neal Bradsher disclose a roughly 40% stake and signal ongoing strategic engagement.

The filing shows Broadwood Partners, Broadwood Capital and Neal C. Bradsher collectively beneficially own 12,835,134 shares, or 39.7%, of Insight Molecular Diagnostics’ common stock, based on 32,318,071 shares outstanding including certain warrants. This represents a highly concentrated position with shared voting and dispositive power over most of the stake.

The group describes itself as using working capital and personal funds, with no special-purpose borrowing, which suggests a conventional long equity investment structure. They explicitly state an intention to review the investment on a continuing basis and to remain in contact with management, the board and other significant shareholders regarding alternatives to “create significant additional shareholder value over time.”

They also reserve the right to act in concert with other holders and to change their share ownership through open-market or privately negotiated transactions, subject to market conditions and securities laws. Future company disclosures or ownership updates will clarify whether this sizeable block leads to board-level influence or specific strategic initiatives.

Broadwood Partners beneficial ownership 12,834,977 shares Insight Molecular Diagnostics common stock, as of the filing date
Broadwood Partners ownership percentage 39.7% Based on 32,318,071 shares outstanding, adjusted for warrants
Neal C. Bradsher beneficial ownership 12,835,134 shares Includes 157 shares with sole power plus shared Broadwood position
Shares outstanding basis 32,318,071 shares Shares outstanding, adjusted to include certain warrants
Shares with shared voting power 12,834,977 shares Shared voting and dispositive power for Broadwood entities and Bradsher
Shares with Bradsher sole power 157 shares Sole voting and dispositive power held directly by Neal C. Bradsher
beneficial owner financial
"As of the date hereof, Broadwood Partners may be deemed to be the beneficial owner of 12,834,977 Shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Schedule 13D regulatory
"The Reporting Persons are filing this /A to report a change in their respective beneficial ownership percentages."
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
pooled investment vehicle financial
"Broadwood Partners is a pooled investment vehicle that is principally engaged in the business of investing its assets in securities."
dispositive power financial
"Broadwood Partners has sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition of 12,834,977 Shares."
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
working capital financial
"The funds for the purchase of the 12,834,977 Shares beneficially owned by Broadwood Partners came from its working capital."
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.





68235C206

(CUSIP Number)
Neal C. Bradsher
c/o Broadwood Capital, Inc., 156 West 56th Street, 3rd Floor
New York, NY, 10019
(212) 508-5735

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
04/23/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Broadwood Partners, L.P.
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher/President of Broadwood Capital Inc.
Date:04/27/2026
Broadwood Capital, Inc.
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher/President
Date:04/27/2026
Neal C. Bradsher
Signature:/s/ Neal C. Bradsher*
Name/Title:Neal C. Bradsher
Date:04/27/2026
Comments accompanying signature:
* This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

FAQ

How much of Insight Molecular Diagnostics (IMDX) do Broadwood and Neal Bradsher own?

Broadwood Partners, Broadwood Capital and Neal C. Bradsher report beneficial ownership of 12,835,134 Insight Molecular Diagnostics shares, representing 39.7% of the company’s common stock. This percentage is based on 32,318,071 shares outstanding, adjusted to include warrants they beneficially own.

Who are the reporting persons in the IMDX Schedule 13D/A filing?

The reporting persons are Broadwood Partners, L.P., Broadwood Capital, Inc., and Neal C. Bradsher. Broadwood Capital is an SEC-registered investment adviser, Broadwood Partners is a pooled investment vehicle, and Bradsher is President of Broadwood Capital and a U.S. citizen.

How did Broadwood fund its Insight Molecular Diagnostics (IMDX) share purchases?

Broadwood Partners funded its 12,834,977 IMDX shares from its working capital. Broadwood Capital’s beneficial ownership comes through Broadwood Partners, and Neal Bradsher’s beneficial stake was funded by his personal funds together with Broadwood Partners’ working capital, without special-purpose borrowing.

What voting power do Broadwood and Neal Bradsher have over IMDX shares?

Broadwood Partners and Broadwood Capital each report shared voting and dispositive power over 12,834,977 shares and no sole power. Neal Bradsher has sole voting and dispositive power over 157 shares and shared power over 12,834,977 shares, aligning his control with the Broadwood entities.

What are Broadwood and Neal Bradsher’s intentions regarding their IMDX investment?

They state they will review their investment on a continuing basis and may discuss alternatives with management, the board and other shareholders. They reserve the right to adjust their holdings or act in concert with others, subject to market conditions and applicable securities laws.

What ownership base did the IMDX Schedule 13D/A use to calculate 39.7%?

The reported 39.7% beneficial ownership is calculated using 32,318,071 Insight Molecular Diagnostics shares outstanding as of the relevant date, as adjusted to include warrants of the issuer that are beneficially owned by the reporting persons, according to the filing.